Jafron Biomedical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Equivalents	470.23	2,516	1,725	2,810	2,559	2,319
Trading Asset Securities	2,162	0.06	593.07	-	-	150.01
Cash & Short-Term Investments	2,632	2,516	2,318	2,810	2,559	2,469
Cash Growth	1.73%	8.55%	-17.52%	9.83%	3.62%	56.79%
Accounts Receivable	66.15	40.3	55.61	81.21	239.64	308.06
Other Receivables	4.03	1.95	3.66	6.51	6.85	6.32
Receivables	70.18	42.25	59.27	87.72	246.49	314.37
Inventory	256.98	291.75	337.79	385	349.13	196.55
Prepaid Expenses	-	0.69	-	0.32	14.55	-
Other Current Assets	75.46	67.37	68.81	28.5	124.32	75.27
Total Current Assets	3,034	2,918	2,784	3,312	3,293	3,056
Property, Plant & Equipment	1,890	1,881	1,894	1,771	1,672	1,272
Long-Term Investments	125.66	308.47	446.13	116.13	69.45	111.2
Goodwill	7.01	7.01	7.01	12.21	37.81	44.07
Other Intangible Assets	99.76	100.66	97.75	100.37	100.43	101.31
Long-Term Deferred Tax Assets	42.32	41.81	34.97	30.35	36.49	26.54
Long-Term Deferred Charges	82.4	86.65	87.19	94.87	59	35.95
Other Long-Term Assets	239.42	64.95	32.35	107.03	148.22	162.91
Total Assets	5,521	5,409	5,383	5,543	5,417	4,810
Accounts Payable	94.13	112.27	119.19	135.62	128.52	60.76
Accrued Expenses	75.95	117.16	125.07	158.21	157.48	192.98
Short-Term Debt	2.16	39.39	77.51	261.83	317.09	-
Current Portion of Long-Term Debt	9.74	7.02	192.2	16.79	-	-
Current Portion of Leases	-	1.58	1.83	3.83	4.73	3.17
Current Income Taxes Payable	83.57	34.37	56.63	30.52	2.55	23.19
Current Unearned Revenue	29.33	30.76	16.86	37.57	42.3	20.65
Other Current Liabilities	53.69	159.54	177.51	185.03	64.52	85.51
Total Current Liabilities	348.56	502.1	766.79	829.42	717.18	386.26
Long-Term Debt	1,225	1,183	1,110	1,381	936.78	897.37
Long-Term Leases	4.14	4.09	4.74	11.35	17.34	17.01
Long-Term Unearned Revenue	223.19	228.64	144.95	151.78	151.66	125.08
Long-Term Deferred Tax Liabilities	17.5	16.4	16.11	16.78	3.12	0.73
Other Long-Term Liabilities	2.96	3.02	6	-	-	-
Total Liabilities	1,822	1,938	2,049	2,390	1,826	1,426
Common Stock	798.61	798.61	798.61	807.56	807.71	805.5
Additional Paid-In Capital	226.67	219.17	231.26	694.14	678.04	618
Retained Earnings	3,052	2,832	2,918	2,408	2,507	2,336
Treasury Stock	-500.02	-500.06	-733.82	-880.63	-509.69	-523.8
Comprehensive Income & Other	122.49	122.49	119.69	118.63	91.7	123.14
Total Common Equity	3,700	3,472	3,334	3,147	3,574	3,359
Minority Interest	-0.26	-0.39	0.76	5.4	16.17	24.79
Shareholders' Equity	3,700	3,471	3,335	3,153	3,590	3,384
Total Liabilities & Equity	5,521	5,409	5,383	5,543	5,417	4,810
Total Debt	1,241	1,235	1,386	1,675	1,276	917.55
Net Cash (Debt)	1,390	1,280	931.31	1,135	1,283	1,552
Net Cash Growth	18.03%	37.49%	-17.97%	-11.49%	-17.34%	-1.47%
Net Cash Per Share	1.82	1.66	1.19	1.43	1.62	1.93
Filing Date Shares Outstanding	787.55	774.36	774.36	774.47	798.87	815.46
Total Common Shares Outstanding	787.55	774.36	774.36	774.47	798.86	815.46
Working Capital	2,686	2,416	2,017	2,482	2,576	2,669
Book Value Per Share	4.70	4.48	4.31	4.06	4.47	4.12
Tangible Book Value	3,593	3,364	3,229	3,035	3,436	3,213
Tangible Book Value Per Share	4.56	4.34	4.17	3.92	4.30	3.94
Buildings	-	1,297	1,296	1,260	890.61	812.74
Machinery	-	823.61	764.58	678.23	514.6	304.98
Construction In Progress	-	272.97	244.45	122.43	473.99	301.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.